The treatment of rheumatoid drugs are generally divided into four categories: First, non-steroidal anti-inflammatory drugs, also known as first-line drugs, mainly including ibuprofen, fotarine, meloxicam, etc., these drugs can generally take effect within a few days, so that the patient’s joint function and quality of life can be improved faster, but the efficacy can not be maintained for a long time, and can not control the progress of the disease; Second, slow-acting anti-rheumatic drugs called second-line drugs, these drugs have a slower onset of action, but But can effectively improve the clinical symptoms, but also can stop or delay the development of the disease, mainly including methotrexate, leflunomide, leucovorin, etc.; Third, glucocorticoids, with a fast onset and effective control of symptoms, improve the role of the disease, but generally only as a slow-acting anti-rheumatic drugs to take effect of the bridge treatment; Fourth, biological agents, with the dual role of regulating the body’s immune response and inhibit the body’s inflammatory response to Rheumatoid treatment has better efficacy, is currently a better prospect in the treatment of drugs, mainly including tumor necrosis factor inhibitors, interleukin I receptor blockers, and anti-CD20 monoclonal antibodies and other drugs.